Center for Drug Evaluation and Research

Center for Drug Evaluation and Research. The Center for Drug Evaluation and Research is a pivotal component of the Food and Drug Administration responsible for ensuring the safety and efficacy of human drug products in the United States. Established in the late 1980s, it oversees the complex evaluation of new pharmaceuticals before they reach the market and monitors their performance afterward. Its work is fundamental to public health, balancing innovation in pharmaceutical development with rigorous regulatory standards to protect consumers.

History and mission

The center was formally created in 1987, succeeding the earlier Bureau of Drugs within the Food and Drug Administration. This reorganization aimed to enhance the agency's scientific capacity and regulatory efficiency in response to evolving challenges like the AIDS epidemic and increasing drug innovation. Its core mission is to protect and promote public health by ensuring that all prescription and over-the-counter drugs are safe and effective for their intended use. This involves a comprehensive lifecycle approach, from pre-clinical research through post-market surveillance, guided by statutes like the Federal Food, Drug, and Cosmetic Act and the Prescription Drug User Fee Act.

Organizational structure

The center is organized into multiple specialized offices that manage different aspects of the drug review process. Key operational units include the Office of New Drugs, which oversees the evaluation of new drug applications, and the Office of Pharmaceutical Quality, which ensures manufacturing standards. Other critical offices are the Office of Surveillance and Epidemiology, responsible for post-market safety, and the Office of Generic Drugs, which reviews abbreviated new drug applications. The center is led by a director and operates under the broader umbrella of the Food and Drug Administration, collaborating closely with other agencies like the National Institutes of Health and the Centers for Disease Control and Prevention.

Regulatory functions and processes

Its primary function is the evaluation and approval of new drug applications through a rigorous scientific process. This involves reviewing extensive data from clinical trials conducted by sponsors like Pfizer or Merck & Co. to assess safety and efficacy. For generic drugs, the center reviews abbreviated applications to demonstrate bioequivalence to an already approved reference listed drug. It also enforces current good manufacturing practices, monitors adverse event reports through systems like FAERS, and can issue regulatory actions such as boxed warnings or product recalls. Many of its activities are funded under agreements established by the Prescription Drug User Fee Act.

Key initiatives and programs

The center has launched several major initiatives to modernize drug regulation and address public health needs. The Drug Development Tools qualification program aims to advance innovative methods for evaluating products. In oncology, programs like Oncology Center of Excellence facilitate the development of treatments for diseases like breast cancer. The Generic Drug User Fee Amendments program has worked to expedite the review of generic applications. Other significant efforts include the Risk Evaluation and Mitigation Strategy framework for high-risk drugs and promoting precision medicine through biomarker identification and targeted therapies.

Impact and controversies

The center's decisions have profoundly impacted medical practice and public health, facilitating access to critical therapies for conditions from HIV/AIDS to COVID-19. Its approval processes, however, have sometimes been at the center of significant debate. Controversies have arisen over the accelerated approval of drugs like Aduhelm, concerns about opioid oversight, and debates regarding the balance between speed and safety, as seen during the COVID-19 pandemic with vaccines and therapeutics like remdesivir. The center continually navigates criticism from industry, patient advocates, and Congress, striving to adapt its regulatory science in a rapidly evolving landscape.

Category:Food and Drug Administration Category:Government agencies established in 1987 Category:Drug regulation in the United States